Asthma Treatment Market: Sales and Prevalent Cases to Grow, but Causes of the Condition Remain Unknown

The global asthma treatment market is estimated to reach a value of $21.6 billion by 2019, due not only to the continuing growth of high prevalence rates, particularly among young children, but also the need for long-term maintenance therapy, according to business intelligence provider GBI Research.
The new report* states that in 2013, the asthma market across the eight major countries (US, Canada, France, Germany, Italy, Spain, UK and Japan) was estimated at $16.6 billion. This value will be boosted over the coming years by the growing number of people affected by the condition, which could reach 400 million by 2025.
By 2019, GBI Research estimates that the US will maintain its status as the major global market for asthma pharmaceuticals, with a share of $12.5 billion, followed by Japan and the UK at $3.2 billion and $2 billion, respectively.
The projected market forecast is based on the expected launch of seven new drugs between 2013 and 2015. The most notable of these is GSK’s Relvar, formerly known as Relovair, and successor to Advair. In September 2013, the Japanese Ministry of Health, Labour and Welfare approved Relvar for use in bronchial asthma. This followed the European Medicines Agency issuing a positive opinion recommending marketing authorization for the drug.
Yasser Mushtaq, GBI Research’s Associate Analyst, says: “The once-daily Relvar is forecast to capture a significant market share within this treatment group, becoming another blockbuster drug within the respiratory market. Furthermore, the highly priced, novel IL-targeting biologics, if approved, will also contribute to growth, although these could still face limitations due to their restricted target populations.
If successful, these therapies could provide a useful alternative for patients with severe asthma, whose symptoms are poorly controlled by treatments such as ICS monotherapy, LABA/ICS combinations and leukotriene inhibitors.
However, the asthma market will be hit by the growth of generic drug sales, as well as by both recent patent expirations and patents due to expire over the next couple of years. Additionally, there are various unknowns about the condition, which have created difficulties for pharmaceutical companies hoping to develop therapies targeted at specific molecular types or clinical symptoms of the disease.
“Despite the pathophysiology of asthma being well described, there remains a limited understanding of the specific interactions that occur between inflammatory cells and mediators that bring about specific clinical manifestations of the disease. Indeed, the exact cause or causes of the condition remain unknown, and are the subject of much ongoing research,” concludes Mushtaq.
*Asthma Therapeutics Market to 2019 — Breakthrough Biologics to Enhance Treatment of Severe Asthma and Drive Market Growth
Related News
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance